Two biosimilars have been approved by the US FDA, and more are going to receive approval soon. With this level of disruption in US retina practice, what do you need know? George Williams, MD, the Senior Secretary for Advocacy at the AAO, joined us for preview on what practice might look like now that biosimilars are a fact of life. Also, Caroline Baumal, MD, sat down with us to discuss the YOSEMITE and RHINE studies, which released 2-year results. How did patients receiving faricimab (Vabysmo, Genentech/Roche) respond during their second year of treatment?